发明名称 |
Class I anti-CEA antibodies and uses thereof |
摘要 |
The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer. |
申请公布号 |
US8771690(B2) |
申请公布日期 |
2014.07.08 |
申请号 |
US201314066097 |
申请日期 |
2013.10.29 |
申请人 |
Immunomedics, Inc. |
发明人 |
Hansen Hans J.;Chang Chien-Hsing;Goldenberg David M. |
分类号 |
A61K39/395 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
Kakashima Richard A. |
主权项 |
1. A method of delivering a therapeutic agent, comprising administering to a subject a chimeric, humanized or human Class I anti-CEA antibody or fragment thereof, wherein the Class I anti-CEA antibody or fragment thereof comprises the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6), wherein the Class I anti-CEA antibody or fragment thereof is conjugated to at least one therapeutic agent. |
地址 |
Morris Plains NJ US |